An interventional study of Screening of the subjects was conducted using an ultrasonic robot. in Breast Cancer and Ultrasound, sponsored by Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to female participants aged 35 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.
Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 3rd largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 238 that started in 2025, is one of 328 with no phase, reaches primary completion later than 514 of the 1,067 other live ones, and was the 1,714th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 35 Years to 64 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,936 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 281 · Phase 2 643 · Phase 3 372 · Phase 4 51
First in 1997; this study’s year is marked. 238 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,525 interventional studies, 240 across the 409 observational. Of the 451 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
490 of 1,936 have an industry lead sponsor. The 10 most frequent:
Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.
Huazhong University of Science and Technology has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
248 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 248 to your calendar (.ics) → With an account.
Among the 1,936 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if robotic ultrasound screening works as well as or better than traditional sonographer-led screening for detecting breast cancer. It will also explore how well participants follow recommended post-screening care. The main questions it aims to answer are:
Does robotic ultrasound screening detect more cases of breast cancer compared to traditional sonographer-led screening? How well do participants follow up on recommended care after robotic ultrasound screening? Researchers will compare robotic ultrasound screening to traditional sonographer-led screening to see if robotic ultrasound works effectively for breast cancer screening.
Participants will:
Receive a breast ultrasound performed either by a robotic system or a human sonographer.
Undergo follow-up management based on their BI-RADS classification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Screening of the subjects was conducted using an ultrasonic robot.
The subjects are scanned with traditional hand-held ultrasound.The images are diagnosed by radiologists.
The ultrasound robot automatically scans the breasts of subjects via its mechanical arm and generates images.The diagnosis is made based on the radiologist's interpretation of the images.
The detection rate of breast cancer
Number of detected ductal carcinoma in situ (DCIS) and invasive breast cancers divided by the total number of screened participants.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Cancer type
Non-invasive cancer (DCIS), early invasive cancer, and invasive cancer.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
The early diagnosis rate
The early diagnosis rate is defined as the number of breast cancer cases with TNM stage 0, I, or IIa divided by the number of women diagnosed with breast cancer or other malignant breast tumors during screening\*100.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Lymph node status
Presence of lymph node metastasis; size, morphology, internal structure, margin characteristics, and vascularity of metastatic lymph nodes.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Breast cancer clinical stage
TNM staging, representing tumor size (T), lymph node involvement (N), and distant metastasis (M).
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Histological Grading of Breast Cancer
The internationally accepted Nottingham Histological Grading System is used. This system provides a semi-quantitative and objective assessment of invasive breast cancer. It evaluates three parameters: the proportion of tubule formation, nuclear pleomorphism, and mitotic count. The scores of the three parameters are added together. A total score of 3-5 indicates Grade 1 (G1, well-differentiated/low grade). A total score of 6-7 indicates Grade 2 (G2, moderately differentiated/intermediate grade). A total score of 8-9 indicates Grade 3 (G3, poorly differentiated/high grade).
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Breast cancer screen recall rate
Breast cancer screen recall is defined as further assessment triggered by abnormal ultrasound findings (BI-RADS 0 or 3 and above). The recall rate is the number of women actually recalled divided by the number of women screened.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
The positive predictive value
The positive predictive value of recall is the percentage of recalled women who are diagnosed with breast cancer.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
The breast cancer biopsy rate
The breast cancer biopsy rate is defined as the number of women who actually underwent biopsy divided by the number of women screened. The positive predictive value of biopsy is defined as the percentage of women diagnosed with breast cancer among those who received a biopsy.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Referral adherence rate
Defined as the average adherence to recommended referral for confirmed diagnosis (biopsy and histopathology). It is calculated as the number of women actually referred divided by the number of women recommended for referral.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Interval cancer incidence
Defined as the proportion of women who had a negative or false-positive screening (i.e., no ductal carcinoma in situ or invasive breast cancer) and were subsequently diagnosed with invasive breast cancer within a certain period after screening. Following the national breast cancer screening guideline recommending screening every 2-3 years, this study will evaluate the interval cancer incidence at 24 months, i.e., the proportion of women diagnosed with breast cancer 24 months after a negative screen or 6-24 months after a false-positive screen.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Breast cancer mortality
Defined as the number of deaths due to breast cancer within 24 months after screening divided by the total number of women screened.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
All-cause mortality
Defined as the total number of deaths from any cause within 24 months after screening divided by the total number of women screened.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Post-screening management adherence
Defined as the proportion of women who completed the recommended follow-up medical actions after screening (referral, re-examination, additional tests, etc.). The adherence rate is calculated as the number of participants who completed the recommended management within the specified time / the number of participants requiring further management \* 100%.
Time frame: After participating in the screening, the subjects will be followed up for 24 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huazhong University of Science and Technology →